Skip to content

A DOSE-DETERMINATION STUDY OF SUGAMMADEX AS A ROCURONIUM DECURARIZATION AGENT IN CHILDREN UNDER 2 YEARS OF AGE

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-521946-82-00
Enrollment
99
Registered
2025-11-12
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-urgent non-cardiac surgical procedure or relative emergency >12h that will require curarisation with rocuronium and decurarisation with sugammadex

Brief summary

Total dose of sugammadex, in mg/Kg, to obtain complete decurarisation: TOFc 4/4 and TOFr ≥ 90%. The total dose is obtained by adding the sub-doses of 0.2 mg/Kg administered cumulatively every 3+/- 1 minute to each child until a TOFr >90% is obtained.

Detailed description

Total dose of sugammadex administered below the recommendations for the adult population: yes / no., Total dose of sugammadex administered greater than the recommendations for the adult population: yes / no., Measurements of curarisation levels (TOFc and, where appropriate, TOFr) before the first injection and after each new injection of sugammadex., ˗ Occurrence of recurarisation phenomena during the decurarisation procedure: yes / no. At each decurarisation measurement, a recurarisation phenomenon was defined as: - A decrease of at least 2 units in TOFc, for subjects who had a TOFc < 4/4 at the previous time; - A gross decrease of at least 20% in TOFr or a return to a TOFc < 4/4, for subjects with a TOFc = 4/4 at the previous time., Intensity of initial block depth: TOFc < 2/4, TOFc ≥ 2/4., Total dose of rocuronium, in mg/Kg (induction + possible re-administrations)., Time (in minutes) between the last administration of rocuronium and the first administration of sugammadex., ˗ Occurrence of post-complete recurarisation, up to 60 minutes after the last administration of sugammadex: yes / no. A recurarisation is defined by the measurement of a TOFc < 4/4 or a TOFr < 90% after having observed a TOFr> 90%., Occurrence of adverse events related to the administration of sugammadex: recurarisation, respiratory events on awakening or in the ICU, drug hypersensitivity.

Interventions

DRUGRocuronium Kabi
DRUGroztwór do wstrzykiwań / do infuzji
DRUGSugammadex Mylan 100 mg/mL solution for injection

Sponsors

Centre Hospitalier Universitaire De Caen Normandie
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
Total dose of sugammadex, in mg/Kg, to obtain complete decurarisation: TOFc 4/4 and TOFr ≥ 90%. The total dose is obtained by adding the sub-doses of 0.2 mg/Kg administered cumulatively every 3+/- 1 minute to each child until a TOFr >90% is obtained.

Secondary

MeasureTime frame
Total dose of sugammadex administered below the recommendations for the adult population: yes / no., Total dose of sugammadex administered greater than the recommendations for the adult population: yes / no., Measurements of curarisation levels (TOFc and, where appropriate, TOFr) before the first injection and after each new injection of sugammadex., ˗ Occurrence of recurarisation phenomena during the decurarisation procedure: yes / no. At each decurarisation measurement, a recurarisation phenomenon was defined as: - A decrease of at least 2 units in TOFc, for subjects who had a TOFc < 4/4 at the previous time; - A gross decrease of at least 20% in TOFr or a return to a TOFc < 4/4, for subjects with a TOFc = 4/4 at the previous time., Intensity of initial block depth: TOFc < 2/4, TOFc ≥ 2/4., Total dose of rocuronium, in mg/Kg (induction + possible re-administrations)., Time (in minutes) between the last administration of rocuronium and the first administration of sugammadex., ˗ Occur

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026